Cinnamon and blood sugar: a real signal too shaky to bank on

Cinnamon can move a blood-sugar reading, but the evidence that it usefully treats diabetes does not hold together: the effect on fasting glucose is inconsistent across trials, and the number that actually tracks long-term control — glycated haemoglobin, or HbA1c — has not budged in the pooled data [s1][s2]. That gap, between a short-term nudge and a durable clinical benefit, is the whole story of cinnamon as a supplement, and it is why the strongest reviews stop short of recommending it.

What the trials measured

The most conservative read comes from a Cochrane review that pooled 10 randomised controlled trials in 577 people with type 1 or type 2 diabetes, using oral cinnamon at a mean dose of about 2 grams a day for 4 to 16 weeks [s1]. Its conclusion was flat: the effect on fasting blood glucose was inconclusive, and there was no statistically significant difference between cinnamon and control in HbA1c, serum insulin or post-meal glucose [s1]. On the evidence it reviewed, cinnamon could not be shown to improve any hard marker of diabetes control.

A later meta-analysis in the Annals of Family Medicine looks more favourable at first glance, and it is the study cinnamon marketing tends to lean on. Across 10 trials in 543 patients, at doses from 120 mg to 6 grams a day for 4 to 18 weeks, cinnamon was associated with a fall in fasting plasma glucose of 24.59 mg/dL (95% confidence interval 40.52 to 8.67), along with drops in total cholesterol of 15.60 mg/dL, LDL cholesterol of 9.42 mg/dL and triglycerides of 29.59 mg/dL, and a small rise in HDL cholesterol of 1.66 mg/dL [s2]. So a signal exists — but the same analysis found no significant effect on HbA1c (−0.16%; 95% confidence interval −0.39 to 0.02), the measure that reflects glucose control over months rather than a single morning [s2].

Why the numbers do not settle it

The reason to treat even the positive result with caution is written into the meta-analysis itself: heterogeneity was high for every outcome except HDL, with the I-squared statistic — a measure of how much trials disagree beyond chance — ranging from 66.5% to 94.72% [s2]. When results scatter that widely, a pooled average is a fragile thing to build advice on, and the authors said as much, noting that the preferred dose and duration remain unclear and that the heterogeneity limits how far the findings can be applied to patient care [s2]. A fasting-glucose dip that is not accompanied by a change in HbA1c is also exactly the pattern you would expect from a weak or transient effect rather than a treatment.

Put the two reviews side by side and the honest summary is not "cinnamon lowers blood sugar" but "some trials show a fasting-glucose reduction, the trials disagree sharply, and long-term control is unchanged" [s1][s2]. That is a long way from the aisle claim that a spice manages diabetes. It sits alongside other everyday items with real but modest metabolic signals — see coffee and type 2 diabetes — where the interesting question is always whether an association survives into a hard outcome.

The coumarin problem

There is also a safety point that gets lost in the health-food framing. Most cheap supermarket and supplement cinnamon is cassia (Cinnamomum cassia), not the more expensive Ceylon type, and cassia is high in coumarin, a compound that can harm the liver at sufficient intake [s1]. An analysis of 104 cinnamon samples bought from EU retailers found that 66.3% either failed international quality standards, breached European food-safety rules, were suspected of fraud, or could be toxic to children because of a high coumarin content [s3]. The reassurance from the trials — that adverse reactions to cinnamon were infrequent and generally mild — was drawn from short studies at ordinary culinary-scale doses, not from the concentrated capsules sold for glucose control [s1].

How to read this

Cinnamon is a case where a real laboratory signal has been inflated into a treatment claim it cannot support. The best-quality review found no clear benefit on any diabetes marker; the more favourable one found a fasting-glucose change but no effect on HbA1c and warned that its own trials were too inconsistent to guide care [s1][s2]. For anyone thinking of it as a substitute for proven glucose management, the evidence is not there, and the coumarin content of common cassia cinnamon is a reason for restraint rather than enthusiasm [s3]. The pattern echoes other single-nutrient pitches, such as selenium for cancer prevention, where the marketing runs well ahead of the trials, and it is a reminder that whole-diet patterns — not a spoonful of one spice — carry the dietary evidence that actually holds up.

This article is informational and not medical or dietary advice; decisions about diabetes treatment or supplements should be made with a qualified clinician.